Press Release

CONTACT:
Fred Kurland
Chief Financial Officer
Corcept Therapeutics
650-327-3270
IR@corcept.com

Corcept Therapeutics to Present at C.E. Unterberg, Towbin
Emerging Growth Life Sciences Conference on October 26, 2005

MENLO PARK, Calif. (October 19, 2005) -- Corcept Therapeutics Incorporated (Nasdaq: CORT) today announced that the company will present at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference on Wednesday, October 26 at 1:20 p.m. (EDT)
at the New York Palace Hotel. The presentation will cover the company's clinical and corporate progress.

A live and subsequent archive of the Corcept presentation will be available on October 26, 2005 via webcast at: http://www.wsw.com/webcast/ceut3/cort/

The webcast will be available for 2 weeks.

ABOUT CORCEPT THERAPEUTICS INCORPORATED

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Corcept's lead product, CORLUX, is currently in Phase III clinical trials for the treatment of the psychotic features of PMD. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in PMD. For additional information about the company, please visit www.corcept.com.